Cisplatin in combination with
zoledronic acid: A synergistic effect in triple-negative breast
cancer cell lines
TONI IBRAHIM, CHIARA LIVERANI, LAURA MERCATALI,
EMANUELE SACANNA, MICHELE ZANONI, FRANCESCO FABBRI, WAINER ZOLI and
DINO AMADORI
[Related article:] Int
J Oncol 42: 1263–1270, 2013; DOI: 10.3892/ijo.2013.1809
Following the publication of the above article, an
interested reader drew an anomaly associated with the presentation
of Fig. 7 to our attention.
Essentially, the panel showing the Cis 0.001 data at T0 for the
BRC-230 cell line was the same as that showing the Cis 0.01
data.
After having re-examined our data, we realized that
an error must have occurred when preparing Fig. 7. A duplication of the photo
corresponding to BRC-230 Cis 0.001 T0 was incorrectly placed in the
position corresponding to BRC-230 Cis 0.01 T0, while the correct
BRC-230 Cis 0.01 T0 figure was erroneously positioned in the
BRC-230 Cis 0.01 T1 slot. Fortunately, we had retained all of the
data on our computer and were able to find the correct photos
representing the conditions of BRC-230 Cis 0.01 T0 and T1.
The correct version of Fig. 7 is shown below. The findings and
conclusions of this paper are still supported by our experimental
data and are not affected by this error. We sincerely apologize for
this oversight and thank the reader for drawing this matter to our
attention. We regret any inconvenience caused by our mistake.
